There were 228 press releases posted in the last 24 hours and 429,274 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Aligos Therapeutics Doses First Subject in Phase 1 Proof-of-Concept Study of Small Molecule Drug Candidate ALG-000184 for Chronic Hepatitis B

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image